Advertisement

Topics

Hikma FY numbers hit by US impairment charge

06:17 EDT 14 Mar 2018 | FinanzNachrichten

A $920m impairment charge on Hikma Pharmaceuticals' West-Ward Columbus business led to the company reporting a hefty $738m full year pre-tax loss on Wednesday. This compares with a profit of $210m ...

Original Article: Hikma FY numbers hit by US impairment charge

NEXT ARTICLE

More From BioPortfolio on "Hikma FY numbers hit by US impairment charge"

Advertisement
Quick Search
Advertisement
Advertisement